PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
0 hedge funds and large institutions have $0 invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 5 closing their positions.
100% less funds holding
Funds holding: 5 → 0 (-5)
100% less capital invested
Capital invested by funds: $15.6K → $0 (-$15.6K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$9.69K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$4K |
| 3 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
-$1K |
| 4 |
IIA
IPG Investment Advisors
San Diego,
California
|
-$864 |
| 5 |
Barclays
London,
United Kingdom
|
-$6 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DCM
1
DAFNA Capital Management
Los Angeles,
California
| – | -$9.69K | -321,856 | Closed |
|
|
2
Acadian Asset Management
Boston,
Massachusetts
| – | -$4K | -172,958 | Closed |
|
|
HLA
3
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
| – | -$1K | -34,208 | Closed |
|
|
IIA
4
IPG Investment Advisors
San Diego,
California
| – | -$864 | -28,700 | Closed |
|
|
5
Barclays
London,
United Kingdom
| – | -$6 | -197 | Closed |
|
PHAS Hedge Fund Activity: Q1 2023 in Review
0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q1 2023, worth a combined $0 — down 100% from $15.6K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PHAS and 0 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was DAFNA Capital Management, exiting entirely with an estimated $9.69K sold.
- 0 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q1 2023, down from 5 in Q4 2022.
- Funds reported $0 of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q1 2023 and 5 closed out, a net change of -5 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q1 2023 was DAFNA Capital Management, an estimated $9.69K sold.
Based on aggregated 13F filings for Q1 2023.